Is luminal A breast cancer curable? Luminal A breast cancer grows very slowly and doesn’t often spread to other cells. Women with luminal A breast cancer have the best chance for a cure and least chance of cancer coming back than any other type of breast cancer. To schedule an appointment with a breast cancer specialist at Main Line Health, call 1.866.
What percentage of breast cancer is luminal A? The luminal-A is the most common subtype and represents 50%-60% of all breast cancers. These tumors frequently have low histological grade, low degree of nuclear pleomorphism, low mitotic activity and include special histological types (i.e., tubular, invasive cribriform, mucinous and lobular) with good prognosis.
Does luminal A breast cancer need chemotherapy? suggested that luminal A requires chemotherapy only when the number of positive lymph nodes is ≥ 4 [11]. The National Comprehensive Cancer Network guidelines recommend that patients with luminal A breast cancer and patients with positive lymph nodes should receive chemotherapy regardless of the number of nodes [12].
What is luminal A and luminal B? The luminal A type is regarded as a low-risk group that shows a good response to endocrine therapy compared to the luminal B type, which is generally of higher grade and has a higher proliferative rate.
Is luminal A breast cancer curable? – Additional Questions
Can luminal A be Grade 2?
Luminal A tumors tend to be: Estrogen receptor-positive (ER-positive) HER2 receptor-negative (HER2-negative) Tumor grade 1 or 2.
What does luminal A mean?
“Luminal A” is one of five main breast cancer subtypes based on this genetic criteria. Breast cancers classified as luminal A are: Progesterone-receptor (PR) and/or estrogen-receptor (ER) positive. Human epidermal growth factor receptor-2 (HER2) negative.
What does luminal B mean?
Advertisement. Luminal B-like breast cancer is estrogen-receptor-positive and HER2-positive and has any level of Ki-67 and may be progesterone receptor-positive or progesterone receptor-negative. Luminal B cancers tend to grow faster than luminal A cancers and have a slightly worse prognosis.
What is Ki-67 a marker for?
Introduction. Ki67 is a nuclear antigen that is an excellent marker of active cell proliferation in the normal and tumor cell populations (1). It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response (2–4).
What does KI-67 stand for?
The Ki-67 percentage score is defined as the percentage of positively stained tumor cells among the total number of malignant cells assessed [11].
What does ER PR positive mean?
If breast cancer cells have estrogen receptors, the cancer is called ER-positive breast cancer. If breast cancer cells have progesterone receptors, the cancer is called PR-positive breast cancer. If the cells do not have either of these 2 receptors, the cancer is called ER/PR-negative.
Is it better to be HR-positive or negative?
What is the survival rate for HR positive breast cancers? The survival rate for breast cancers are excellent if the cancer is detected early, and in general HR positive cancers grow slower and have a better prognosis. Overall, breast cancers that are both HR positive and HER2 negative have the best outcomes.
Is it good to be ER positive?
In general, ER-positive, HER2-negative breast cancers that are low grade, strongly ER and progesterone receptor (PR) positive, with low measures of proliferation have a good prognosis with endocrine treatment alone.
Is it better to be HER2-negative or positive?
Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein.
Do you need chemo if you are HER2-negative?
Many women with hormone-positive, HER2-negative, lymph node-negative early-stage breast cancer who have intermediate risk of cancer recurrence do not need chemotherapy. The exception is that some women who are younger than 50 may benefit when chemotherapy is added to hormone therapy.
Does HER2-positive mean metastatic?
Since this protein can make cancer cells grow more quickly, it’s natural to worry that your HER2-positive breast cancer might spread, or “metastasize.” If breast cancer spreads to other parts of your body, doctors call it “metastatic.” That means it’s at a more advanced stage than if it’s only in your breasts.
Can HER2-positive be cured?
HER2-positive breast cancer is highly curable because of the availability of these HER2-targeted therapies, so we treat patients fairly aggressively upfront to reduce the risk of them experiencing a stage IV recurrence.
How long can you live with HER2?
The survival rate among patients differ based on the molecular subtype and stage. The survival rate at four years among women with HR+/HER2− is estimated to be 92.5%, followed by HR+/HER2+ at 90.3%, HR−/HER2+ at 82.7%, and HR−/HER2− at 77.0% [1].
How long is chemo for HER2-positive?
Neoadjuvant therapy is typically administered for between 12 and 20 weeks, depending on the chosen regimen, and followed by surgery. When given as adjuvant chemotherapy following surgery, trastuzumab is given concurrently with chemotherapy, then continued for a total duration of 12 months.
How do you stop HER2 recurrence?
Vaccine Derived from HER2 Protein May Help Prevent Breast Cancer Recurrence. A new breast cancer vaccine that is derived from the HER2 protein may help prevent recurrence in patients with HER2-positive disease and appears safe.
Does HER2 always return?
HER2-positive breast cancer is more aggressive and more likely to recur, or return, than HER2-negative breast cancer. Recurrence can happen anytime, but it usually takes place within 5 years of treatment. The good news is that recurrence is less likely now than ever before.
What are the chances of HER2 coming back?
The researchers found: 10% to 23% of women diagnosed with small, HER2-positive cancer had a recurrence within 5 years of diagnosis compared to about 5% of women diagnosed with HER2-negative cancer.
